Tag:

ICON

Latest Headlines

Latest Headlines

Icon and Medidata unite to give patients a louder voice in clinical trials

CRO magnate Icon and and eClinical outfit Medidata are pooling their resources to offer a combined platform for patient-reported outcomes in clinical trials, touting their technology as faster and more effective in surveying participants.

Icon charts another sales jump with eyes on a big year

CRO giant Icon continued its steady progress with another double-digit quarter of sales growth, piling up revenue with hopes of clearing $1.5 billion this year.

Pfizer and Roche join Icon's adaptive-trial alliance

Pfizer and Roche are the latest pharma heavyweights to join Icon's consortium of drugmakers working to flesh out new technology for adaptive clinical trials, allowing study sponsors to react to results in real time and maximize efficacy.

Icon will teach Cambridge students how to market drugs

Global CRO Icon has deepened its longstanding relationship with Cambridge University, agreeing to lead a class on pricing and market access for new drugs.

Icon wraps up its $143.5M deal for Aptiv

Irish CRO Icon has closed out its $143.5 million acquisition of Aptiv Solutions, a deal designed to amp up its technology and expand its presence in Japan.

Icon cranks up its 2014 expectations after another leap

CRO Icon posted another double-digit revenue jump in its fiscal first quarter, and now the Irish outfit is upping its annual guidance, counting on M&A and an expanding market share to pad its profits.

Big Pharma megadeals could spell trouble for CROs

When Big Pharma execs talk up "synergies" to convince shareholders to buy into mergers, they mean, in part, consolidating contractors. And, with all the megadeals rumored and real surfacing over the past week, CROs could be in for a revenue haircut as the drug business realigns.

Icon is buying Aptiv with a focus on adaptive trials

CRO giant Icon has agreed to trade $143.5 million for Aptiv Solutions, looking to complement its own technology in complex trial design and expand its presence in Japan.

After soaring 20% in 2013, Icon eyes a bigger share of the CRO market

Icon watched its revenue swell by 20% last year, and now the Irish CRO is expecting a healthy rate of new business wins to fuel growth in 2014.

Icon rolls out data visualization tech for adaptive trials

Icon, like most of the world's largest CROs, is investing in high-tech adaptive trial monitoring, and the company's latest offering allows investigators to comb through huge dumps of lab data in real time, tracking trial trends as they happen.